In a 20-year-old woman with a two-year history of spontaneous nipple discharge and mildly elevated serum prolactin, what is the appropriate next step in management?

Management of Nipple Discharge with Mildly Elevated Prolactin

In this 20-year-old woman with 2-year history of nipple discharge and mildly elevated prolactin (32.8 ng/mL), the next step is to obtain an MRI of the pituitary gland to evaluate for a prolactinoma, after first excluding medication use, hypothyroidism, and renal failure. 1

Diagnostic Workup Algorithm

Step 1: Exclude Secondary Causes

Before proceeding with imaging, you must systematically rule out 1:

• Medication review: Antipsychotics, antidepressants, antihypertensives, and gastrointestinal agents are common culprits
• Thyroid function: Check TSH to exclude hypothyroidism
• Renal function: Check creatinine/BUN to exclude renal failure
• Pregnancy test: Essential in any reproductive-age woman

Step 2: Assess for Macroprolactin

Consider screening for macroprolactin in asymptomatic patients with hyperprolactinemia 1. Macroprolactin is a biologically inactive, high-molecular-weight form of prolactin that can cause falsely elevated readings without clinical significance. This is particularly relevant since your patient has had persistent elevation for 2 years. If macroprolactin accounts for the elevation, no treatment is necessary 2.

Step 3: Obtain Pituitary MRI

With a prolactin level of 32.8 ng/mL (mildly elevated) and unexplained hyperprolactinemia after excluding secondary causes, pituitary MRI is indicated 1, 3. The Endocrine Society guideline is clear that patients with unexplained elevations require imaging of the sella turcica 4.

Important caveat: The degree of prolactin elevation correlates with tumor size. Prolactin levels >200 ng/mL strongly suggest a macroadenoma, while mild elevations (like 32.8) typically indicate either a microprolactinoma or non-tumor causes 1.

Characterizing the Nipple Discharge

The nipple discharge characteristics matter for overall management 5, 6:

Pathologic features (requiring surgical referral):

• Spontaneous discharge
• Unilateral
• Single-duct origin
• Bloody or serous

Physiologic features (typically benign):

• Provoked/expressed discharge
• Bilateral
• Multiple ducts
• White, green, or yellow color

Your patient's 2-year history suggests this is likely galactorrhea related to hyperprolactinemia rather than a concerning breast pathology, but the discharge characteristics should be documented.

Treatment Considerations

If Microprolactinoma is Found:

For asymptomatic patients with microprolactinomas, treatment with dopamine agonists is optional 1. The guideline suggests not treating asymptomatic microprolactinomas, but recommends treatment for those with amenorrhea or bothersome symptoms.

If treatment is indicated 1, 3, 7:

• Cabergoline is first-line: More effective and better tolerated than bromocriptine
• Starting dose: 0.25-0.5 mg twice weekly
• Normalizes prolactin in 80-90% of cases
• Superior tumor shrinkage compared to bromocriptine (>90% vs 66%)

If No Tumor is Found (Idiopathic Hyperprolactinemia):

Treatment depends on symptoms 1:

• If asymptomatic with regular menses: Observation is acceptable
• If symptomatic (amenorrhea, bothersome galactorrhea): Consider dopamine agonist therapy
• Alternative: Oral contraceptives can be used for menstrual regulation in microadenomas

Common Pitfalls to Avoid

1. Don't obtain serial prolactin measurements: A single elevated level confirms hyperprolactinemia if obtained without excessive venipuncture stress 1

2. Don't perform dynamic prolactin testing: This is not recommended for diagnosis 1

3. Don't skip the medication review: Drug-induced hyperprolactinemia is extremely common and often overlooked 7

4. Don't assume all elevated prolactin needs treatment: Asymptomatic microprolactinomas can be observed 1

5. For very large tumors with only mildly elevated prolactin: Consider the "hook effect" and request serial dilutions to avoid falsely low readings 1

Long-term Management

If treatment is initiated and successful 1:

• After 2 years of normalized prolactin and no visible tumor on MRI, consider tapering/discontinuing dopamine agonist
• Recurrence risk ranges 26-69%, highest in the first year after withdrawal
• Recurrence is predicted by initial prolactin level and tumor size
• Long-term surveillance is necessary even after withdrawal